Search Results 361-370 of 22921 for breast
placebo in combination with ado-trastuzumab emtansine (TTT-DM1) in patients with stage II-III HER2+ breast cancer with residual disease post-neoadjuvant ...
From early detection to targeted therapies, breast cancer survival has reached record highs with Mayo Clinic leading what's next. Learn more.
Analyzing the genetic makeup of breast cancer cells to understand how DNA changes affect response to cancer treatments and personalize treatment options.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Last chance! Your gift today has 5X the power to fuel medical progress using AI.